(Circulation. 2007;115:e213.)
© 2007 American Heart Association, Inc.
Correspondence |
Cardiovascular Division, Brigham and Womens Hospital, Boston, Mass
Cardiology Division, Massachusetts General Hospital, Boston, Mass
We thank Drs Calonge and Petitti for their letter regarding our article.1 However, we remain concerned about the lack of precision in the task forces position. The recommendation statement on screening for peripheral arterial disease (PAD)2 suggests that:
The USPSTF found fair evidence that screening with ankle brachial index can detect adults with asymptomatic PAD. The evidence is also fair that screening for PAD among asymptomatic adults in the general population would have few or no benefits because the prevalence of PAD in this group is low and because there is little evidence that treatment of PAD at this asymptomatic stage of disease, beyond treatment based on standard cardiovascular risk assessment, improves health outcomes [emphasis added] [p 1].
The letter by Drs Calonge and Petitti reiterates the same point by reporting that the "intention of the USPSTF recommendation was clear: It was intended only to address PAD screening to improve the health outcomes for PAD." We would agree that a screening ankle brachial index measurement in asymptomatic patients would not reduce adverse leg outcomes for PAD. However, we would include myocardial infarction, stroke, and death as health outcomes for PAD. This single word substitution, "health" rather than "leg," forms the basis for misunderstanding by practitioners.
PAD affects more than 15% of the population >70 years of age and a substantial proportion of those who have smoked or have diabetes.3 Cardiovascular event rates are higher in people with abnormal ankle brachial index, independently of risk factors such as high cholesterol, diabetes, and smoking.4 PAD is atherosclerosis, not a risk factor for atherosclerosis. Therefore, detecting atherosclerosis in an asymptomatic patient may prompt physicians to intensify their treatment strategies, such as lowering low-density lipoprotein cholesterol to <100 mg/dL or prescribing aspirin independently of extant risk factors.5,6
We wish to be specific: Screening asymptomatic adults will not lower the rates of intermittent claudication, critical-limb ischemia, or amputation. Targeted screening of adults, as made clear in our editorial, is likely to reduce heart attack, stroke, and death in patients with asymptomatic PAD, and these are important health outcomes.
| Acknowledgments |
|---|
None.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |